Pagina 13 - I migliori medici di Risonanza magnetica di un'area - TOP-562medici

Education and Specialization

• Bachelor’s Degree: Çukurova University Faculty of Medicine (1987/1993)
• Medical Specialization: Department of Pediatrics, Fırat University (1993/2001)
• Subspecialty: Pediatric Neurology Unit, Hacettepe University (2002/2004)

Professional Experience

• General Practitioner: Mardin State Hospital, Emergency Department (1993/1996)
• Research Assistant: Faculty of Medicine, Fırat University (1996/2001)
• Lecturer: Faculty of Medicine, İnönü University (2001/2002)
• Subspecialty Research Assistant: Faculty of Medicine, Hacettepe University (2002/2004)
• Assistant Professor: Faculty of Medicine, İnönü University (2004/2008)
• Associate Professor: Faculty of Medicine, İnönü University (2008/2014)
• Professor: Faculty of Medicine, İnönü University (2014/2023)

Il Dottor Victor Alexander Krol è il Primario di gastroenterologia, medicina interna e del centro per il trattamento dell'obesità presso l'ospedale Martinus.

Il Dottor Victor Alexander Krol è uno specialista altamente qualificato, responsabile dei reparti di gastroenterologia e medicina interna. Con molti anni di esperienza e una profonda conoscenza del suo campo, il dottor Krol si è affermato come un esperto eccezionale, offrendo ai pazienti trattamenti completi e un approccio personalizzato. Utilizza attivamente le più recenti metodiche di diagnosi e trattamento delle malattie gastrointestinali, del metabolismo, nonché delle malattie del sistema cardiovascolare e respiratorio.

Il Dottor Krol è anche il direttore del Centro certificato per il trattamento dell'obesità presso l'ospedale Martinus, dove vengono eseguiti trattamenti chirurgici ed endoscopici per l'obesità. In questo centro vengono applicate tecnologie all'avanguardia per la diagnosi e la terapia dell'obesità (adiposità), che includono metodi come la chirurgia bariatrica, la riduzione del peso endoscopica e programmi specializzati per pazienti con diversi stadi di obesità. Il centro è certificato secondo alti standard e ha ottimi risultati nel trattamento di questa grave malattia.

Il reparto di gastroenterologia sotto la guida del dottor Krol si occupa della diagnosi e trattamento delle malattie dello stomaco, intestino, fegato, pancreas e cistifellea. I medici del reparto utilizzano una vasta gamma di metodi, inclusi procedure endoscopiche, ecografie e altre moderne tecnologie diagnostiche.

Il reparto di medicina interna copre un ampio spettro di malattie, tra cui cardiologia, diabetologia, infettivologia e terapia delle malattie respiratorie e renali. Il dottor Krol e il suo team garantiscono un approccio completo al trattamento, utilizzando i metodi più avanzati della medicina.

Grazie all'elevato livello di professionalità e all'approccio umano verso ogni paziente, il dottor Krol gode di meritato rispetto tra colleghi e pazienti.

Prof. Emin Tireli, MD, is a leading pediatric cardiovascular surgeon. He has performed over 6,329 congenital cardiac surgeries since 1993. He is known worldwide for being one of the first to use the complex Nikaidoh procedure for transposition of the great arteries (TGA).

Dr. Tireli performs more than 100 neonatal cardiac surgeries each year. His expertise includes arterial switch operations, total pulmonary return anomalies, pulmonary banding, and Norwood procedures. He has used hybrid techniques in 15 cases. Dr. Tireli has also completed 30 reconstructions of aortic anomalies and many PDA ligations in extremely low birth weight infants. His work greatly supports neonatal care.

Il medico è un chirurgo ortopedico e di sostituzione articolare con oltre 28 anni di esperienza. Specializzato nel trattamento conservativo e operativo dell'osteoartrite, il medico è esperto in endoprotesi minimamente invasive dell'articolazione dell'anca e nel trattamento delle fratture periprotesiche degli arti inferiori.<\/p>

Laureato presso la Ruprecht-Karls-Universität di Heidelberg, Germania, il medico ha anche esperienza nella chirurgia artroscopica per lesioni sportive. Con numerose pubblicazioni a suo credito sia a livello nazionale che internazionale, il medico è riconosciuto per i suoi contributi al campo.<\/p>

1997 - 2002 Università di Istanbul, Facoltà di Medicina, Cerrahpaşa, Dipartimento di Ortopedia e Traumatologia

1990 - 1996 Università di Istanbul, Facoltà di Medicina, Cerrahpaşa

Articoli che ha scritto e a cui ha partecipato;

Efficacia clinica delle iniezioni peritendinee di plasma ricco di piastrine nel trattamento delle tendinopatie: uno studio retrospettivo Aybars Kıvrak* (a), Mehmet Can Ünlü (a), Eşref Terzi (a), Olgar Birsel (b), Doruk Akgün (c), Yusuf Pirinççi (d), Gokhan Kaynak (a), Isık Akgün (e) Effetti a medio e lungo termine dell'anello acetabolare e delle cellule antiprotrusione Burch-Schneider nelle revisioni acetabolari in pazienti con deficit osseo acetabolare Corrispondenza: Yusuf Pirinççi, Muhammed Taha Demir, Mumammet Salih, Fahri Erdoğan, Necat Guney

I parametri dimensionali del femore prossimale nello sviluppo della displasia dell'anca adulta suggeriscono che una struttura conica, rettangolare a press-fit può essere la scelta ottimale per i pazienti con un'anca di tipo IV secondo Crowe.

Specialità

Chirurgia dello sport

Lacerazioni del menisco

Rotture del legamento crociato anteriore

Protesi di ginocchio

Protesi d'anca

Protesi di spalla

Riparazione del labbro glenoideo

Aumento dell'altezza

Chirurgia dei tumori

Chirurgia del piede (alluce valgo)

Piede diabetico

Infezioni ossee (osteomielite)

Dr. Adil Turan is a specialist in Orthopedics and Traumatology. He completed medical school at Trakya University (1996–2003). He finished his residency at İzmir Bozyaka Training and Research Hospital (2004–2009). In 2020, he conducted trauma research at Denver Health Hospital in Denver, USA.

He worked at Kızıltepe State Hospital (2009–2010). He then served as an Orthopedic Specialist at Antalya Training and Research Hospital (2010–2013) and Ordu State Hospital (2013–2015). He was Chief Assistant at Antalya Training and Research Hospital (2016–2020). He was Associate Professor and Instructor at Antalya Training and Research Hospital (2020–2022) and at the Health Sciences University Antalya Health Application Center (2023).

His professional memberships include the Turkish Orthopedics and Traumatology Association, the Turkish Sports Injuries Arthroscopy and Knee Surgery Association, the Turkish Orthopedics and Traumatology Education Council (since 2016), and the Turkish Medical Association.

Personal Information

Name Surname : Serdar TOKER
Place of Birth - Year :    Istanbul - 1972
Academic Title : Assoc. Dr.
Foreign Language : English

Education

Ege University Faculty of Medicine - Graduation
Sisli Etfal Training and Research Hospital - Specialised
Work Experience

1998 - 2003 Sisli Etfal Training and Research Hospital
2003 - 2004 Kars State Hospital
2004 - 2006 Erzurum Regional Training and Research Hospital
2006 - 2009 Dumlupınar University Faculty of Medicine, Department of Orthopaedics and Traumatology 
2009 - 2010 Research Fellow. Colorado University Denver Healt Centre Rocky Mountain Regional Trauma Centre Department of Orthopaedics and Hand Surgery
2010 - 2016 Necmettin Erbakan University Department of Orthopaedics and Traumatology. Head of Hand Surgery Department
Courses - Seminars and Certificates Received

2013 FESSH (Federation of European Societies for Surgery of the Hand) European Diploma
2015 RMCD Microsurgery Course Course Chair
2015 National Turkish Orthopaedics and Traumatology Congress Speaker
2015 RMCD Congress Speaker
2014 National Turkish Orthopaedics and Traumatology Congress Speaker
2013 - 2014 Rıdvan Ege Hand Surgery Course Instructor
2013 RMCD Microsurgery Course Instructor
2013 RMCD Congress Session Chair
2012 Shoulder Elbow Surgery Course Instructor
2012 Subspeciality Diploma in Hand Surgery
2011 RMCD Microsurgery Course
2009 Ankle Arthroscopy Course
2008 Knee Arthroscopy Course
2005 Ilizarov Applications Course

Prof. İbrahim Azboy, M.D.

Languages: English, Kurdish, Arabic

Orthopaedics and Traumatology
 

Areas of Expertise and Interest

• Hip & knee arthroplasty (primary, revision, robotic‑assisted)
• Infection prevention & management in joint replacements
• Minimally invasive and joint‑preserving orthopedic surgery
• Sports & trauma-related injuries (e.g. ACL, fractures)
• Osteoarthritis, cartilage damage & osteonecrosis

International Researcher IDs:  

• ORCID: 0000-0003-0926-3029 / Yoksis Researcher ID: 145243 

Education & Training

• 1994–2001: Hacettepe University, Faculty of Medicine
• 2002–2008: Ministry of Health Istanbul Training and Research Hospital
• 2014 & 2017: Hospital for Special Surgery, New York, USA – Knee and Hip Arthroplasty and Arthroscopy Training
• 2016: Rothman Institute, Thomas Jefferson University, Philadelphia, USA – Knee and Hip Arthroplasty and Hip Preserving Surgery Training

Academic & Professional Appointments

• 2021–Present: Professor, Istanbul Medipol University
• 2017–2020: Associate Professor, Istanbul Medipol University
• 2011–2017: Assistant Professor, Dicle University
• 2008–2011: Consultant MD, Şanlıurfa and Balıkesir Military Hospitals

Professional Memberships

• Member of 9 national and international orthopedic associations including:
  AAHKS, SICOT, EHS, KADAD, TOTBID, TOTEK, and TTB

Scientific & Educational Contributions

• Prof. Dr. İbrahim Azboy has authored over 70 internationally and 25 nationally peer-reviewed journal articles, contributed to 4 book chapters and 2 book translations, and presented at 25+ international and 65+ national congresses. He also serves as a reviewer for 13 scientific journals, including JBJS, JOA, SICOT-J, and JORR.

Teaching & Speaking Engagements

• Speaker/trainer in 20+ national courses and congresses on topics such as:
• Hip and knee arthroplasty
• Prosthetic joint infections
• VTE prophylaxis
• Surgical approaches and implant strategies

Dr. Fırat Oruç is an Orthopedics and Traumatology specialist with 20 years of experience (since 2005). He has worked at Medical Park Antalya Hospital Complex since 2008. He previously worked at Private Lara Hospital (2005–2007) and completed his military service at GATA Istanbul (2007–2008).

Clinical focus includes knee, shoulder, and hip surgery; joint prostheses; soft tissue and bone tumors; pediatric orthopedics; and hand surgery. He earned his medical degree from Akdeniz University Faculty of Medicine (1993–1999). He completed his Orthopedics and Traumatology residency at Akdeniz University (1999–2005).

Dr. LV Xiao Jun is the Executive Director of the Department of Medical Oncology. He is a national expert in psycho-oncology and has 30 years of clinical experience. He previously served at the First Affiliated Hospital of Xiamen University. He is a recognized expert in cancer treatment and lung cancer care in Fujian Province.

Clinical focus: comprehensive care for solid tumors, including lung, breast, and gastrointestinal cancers; palliative care in oncology; and screening and treatment for psychological distress.

Appointments: Standing Committee Member (third term), Psycho-Oncology Committee, Chinese Anti-Cancer Association; Standing Committee Member (third term), Lung Cancer Committee, Fujian Anti-Cancer Association.

Professional experience

• 2018 – present : Head of the Traumatology Department at the International Orthopaedic Center Hospital Ruber Internacional in Madrid.
• 2000 – 2018 : Specialist in Hip and Knee Surgery at the International Center Hospital Ruber Internacional, Madrid.
• Until 2000 : Deputy Head of the Traumatology Department at the Hospital J. Puerta de Hierro, Madrid.

Education and qualifications

• 1992 : Medical degree from the Faculty of Medicine and Surgery of the Autonomous University of Madrid.
• Specialization in Orthopedic Surgery and Traumatology at the Puerta de Hierro Hospital.

Scientific research and clinical trials

1. Phase 2B : Efficacy and safety study of PD 0348292 for the prevention of venous thromboembolic events (VTE) in patients undergoing total knee arthroplasty.
2. CV185-047 : Comparison of the efficacy of apixaban and enoxaparin for the prevention of VTE.
3. CV185-035 : A study of prevention of deep vein thrombosis after hip replacement.
4. PRADAXA® 1160.85 : A study of the efficacy of dabigatran etexilate for the prevention of VTE following hip and knee surgery.
5. PRADAXA® 1160.84 : Evaluation of the safety of dabigatran in patients with moderate renal impairment after total renal arthroplasty.

Learning and Teaching

• 1997–2000 : Associate Professor, Department of Traumatology, Puerta de Hierro Hospital, Madrid.

Specialization and innovation

• Knee replacement : Using the latest generation navigation systems, Rapid Recovery and ERAS protocols for accelerated recovery.
• Hip Replacement : Minimally Invasive Techniques and Improved Restorative Protocols.
• Arthroscopic surgery : Treatment of diseases of the knee and hip joints.
• Non-surgical treatment : Introduction of innovative infiltration techniques for joint pathology.

Recognition and achievements

• 2022 : Included in the Forbes list as one of the 100 best doctors in Spain , recognized for leadership and innovation in joint surgery using navigation technologies.
• Since 2008 : ISO 9001:2008 certification for quality of hip and knee replacement surgeries.

Membership in professional organizations

• International Member of the American Academy of Orthopaedic Surgeons .
• Member of the Spanish Association of Arthroscopy .

The doctor has established himself as a pioneer in the field of joint surgery, introducing innovative technologies such as navigation systems and minimally invasive approaches. His achievements and approach to patient recovery make him one of the leading specialists in Spain.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Education

• 1986-1989, Bursa High School, Bursa, Turkey
• 1989-1995, Istanbul University, Istanbul School of Medicine, Turkey
• 1999-2003, (Residency) Kadir Has University, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey
• 2015, (Associate Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2021, (Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

Experience

• 1995-1999, Şişli Florence Nightingale Hospital, Istanbul, Cardiology Department
• 2003, Gayrettepe Florence Nightingale Hospital, Istanbul, Department of Radiation Oncology
• 2015, (Associate Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2021, (Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

Prof. Cengiz KÖKSAL, M.D.

Cardiovascular Surgery

Areas of Expertise

• Minimally invasive mitral valve repair and replacement
• Off-pump (beating heart) mitral valve surgery
• Minimally invasive aortic valve replacement
• Minimally invasive coronary bypass surgery
• Carotid (neck artery) surgery
• Aesthetic varicose vein surgery
• Non-surgical treatment of arterial/venous aneurysms in the legs

Education

• Primary Education – Afyon, Turkey
• Secondary & High School – Darüşşafaka High School, Graduated as Top of Class
• M.D., Doctor of Medicine – Istanbul University, Istanbul Faculty of Medicine, 1992
• Specialization in Cardiovascular Surgery – Cerrahpaşa Faculty of Medicine, Istanbul University (1992–1998)

Career

• Cardiovascular Surgeon – Süreyyapaşa Chest, Heart and Vascular Diseases Hospital (2001–2007)
  • Contributed to the foundation of the Cardiovascular Surgery Clinic
  • Achieved Associate Professor title in 2005
• Senior Surgeon – Kartal Koşuyolu High Specialization Training and Research Hospital (2007 onward)
  • Appointed Deputy Chief of Cardiovascular Surgery in 2009
  • Clinical Educator from 2011 to 2017
  • Performed over 2,000 open-heart and vascular surgeries
  • Education Supervisor of the Cardiovascular Surgery Clinic (2016–2017)
• Professor – Bezmialem Vakıf University, Faculty of Medicine (2017–2024)
  • Head of Cardiovascular Surgery Department
• Current Position – Medipol University, Medipol Acıbadem Regional Hospital (Since July 2024)

International Training and Grants

• Leonardo da Vinci EU Scholarship Winner, Portugal (2012)
• Advanced trainings in minimally invasive mitral valve surgery (without sternotomy or heart-lung machine) conducted in:
  • Israel, Portugal, United Kingdom, Italy, Germany (2012–2016)

Achievements & Honors

• "Physician of the Year", Ibn Sina 1000th Year Medical Awards (2018)
• Only physician in Turkey authorized to educate and practice off-pump mitral valve repair
• Organizer of annual Mitral Valve Repair Workshops with national and international participation
• President, National Vascular and Endovascular Surgery Association (2016–2018)
• Editor, the most comprehensive vascular surgery textbook published in Turkish

Academic Contributions

• 80+ peer-reviewed international scientific articles
• 75+ national publications
• Authored 4 book chapters

Delivered 

200+ presentations

 in national and international conferences (since 2011)

Dr. Lee Kyung Hoon is an orthopedic specialist and department head. He treats degenerative arthritis and knee and hip disorders. He performs knee arthroscopy and arthroplasty. He also treats foot and ankle conditions, shoulder problems such as frozen shoulder and rotator cuff tears, osteoporosis, and fractures and other extremity injuries.

He earned his MD from The Catholic University of Korea. He completed his orthopedic residency at The Catholic Medical Center. He finished a fellowship and served as a clinical instructor at Bucheon St. Mary’s Hospital.

He has served as department head at Nasarath International and Himchan General Hospital Incheon. He was also director at Himchan Hospital Incheon and Medrex Hospital. He is a full member of the Korean Orthopedic Association, the Korean Knee Society, the Korean Fracture Society, the Korean Hip Society, the Korean Arthroscopy Society, and the Catholic University Knee Research Society. He completed TPI training and a microsurgery workshop.

Dr. Yan Zhi Ping is the Director of the Radiology Department at Xiamen Humanity Hospital. He graduated from the First Military Medical University. He has authored more than 30 papers. He has edited and contributed to several monographs. He received a Fujian Provincial Third Prize for Science and Technology Progress and two Xiamen Municipal Second Prizes. His expertise includes CT and MRI of the central nervous system, musculoskeletal system, thoracic, and abdominal diseases. He also focuses on cerebral functional imaging. He is skilled in the early diagnosis and differential diagnosis of lung cancer and brain tumors.

Appointments: Standing Committee Member of the Radiology Branch of the Fujian Association of Integrative Medicine. Standing Committee Member of the Fujian Radiological Society. Vice Chairman of the Xiamen Radiological Society. Vice Chairman of the Radiology Branch of the Xiamen Medical Doctor Association. Deputy Director of the Xiamen Radiology Quality Control Center.

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Il medico è specialista in radiologia diagnostica e terapia minimamente invasiva, con un focus sull'ablazione a microonde dei tumori del fegato e dei polmoni sotto guida TC. Laureato all'Università Johannes-Gutenberg, il medico ha ottenuto la licenza medica nel 1988 e ha intrapreso una carriera in radiologia, diventando medico senior all'Università Ruprecht-Karls di Heidelberg. Successivamente, il medico ha servito come Medico Capo presso la Clinica Nordwest a Francoforte sul Meno ed è ora Professore Associato all'Università di Heidelberg.<\/p>

Il medico guida il centro di ablazione FUS guidato da MRI nella regione del Reno-Meno, offrendo trattamenti non chirurgici per varie condizioni. Il medico è membro onorario di DeGIR e ha ricevuto la Medaglia d'Oro di Professore Onorario dall'Università Medica di Osaka.<\/p>